Background: The guide for the use of genotype-guided warfarin dosing in patients for the treatment of non-valvular atrial fbrillation (NVAF) is still lacking.Aim: We aimed to evaluate whether genotype-guided warfarin dosing is superior to conventional clinical dosing for the outcomes of interest in Chinese patients.Method: The patients of this study were assigned to two cohorts to receive their dose of warfarin determined by a genetic and clinical factor (gene group) or dosing determined empirically(control group).We incorporated CYP2C9 and VKORC1 genotypes into the gene group. The international normalized ratio (INR) measurement and standard protocols were used for further dose adjustment in both groups. The primary outcomes were the percentage of time in the therapeutic range (%TTR) and INR measurement during follow up. Secondary safety outcome included bleeding and thrombotic events.Results: Compared with the control group, the average TTR of the gene group was higher(68.4 ± 20.6) % vs (48.5 ± 21.6) %, P<0.001) .The frequency of the average INR monitoring times of the gene group was lower(P=0.02).At the end of follow-up, the gene group had a signi cant lower risk of cumulative incidences of ischemic stroke events in the adjusted model [relative risk (RR) 0.4 (95% CI 0.2 to 0.8),P =0.008] than control group. Conclusion: Genotype-guided warfarin administration increases the average TTR, reach higher TTR levels in the early anticoagulant phase and signi cantly reduce the risk of ischemic stroke events. Impact Statements• The utility of genotype-guided dosing of warfarin can optimize individual warfarin dosing in Chinese AF patients.• Genotype-guided warfarin administration increases the average TTR, reach higher TTR levels in the early anticoagulant phase and signi cantly reduce the risk of ischemic stroke events.
Background: The guide for the use of genotype-guided warfarin dosing in patients for the treatment of non-valvular atrial fbrillation (NVAF) is still lacking. Aim: We aimed to evaluate whether genotype-guided warfarin dosing is superior to conventional clinical dosing for the outcomes of interest in Chinese patients. Method: The patients of this study were assigned to two cohorts to receive their dose of warfarin determined by a genetic and clinical factor (gene group) or dosing determined empirically(control group).We incorporated CYP2C9 and VKORC1 genotypes into the gene group. The international normalized ratio (INR) measurement and standard protocols were used for further dose adjustment in both groups. The primary outcomes were the percentage of time in the therapeutic range (%TTR) and INR measurement during follow up. Secondary safety outcome included bleeding and thrombotic events. Results: Compared with the control group, the average TTR of the gene group was higher(68.4 ± 20.6) % vs (48.5 ± 21.6) %, P<0.001) .The frequency of the average INR monitoring times of the gene group was lower(P=0.02).At the end of follow-up, the gene group had a significant lower risk of cumulative incidences of ischemic stroke events in the adjusted model [relative risk (RR) 0.4 (95% CI 0.2 to 0.8),P =0.008] than control group. Conclusion: Genotype-guided warfarin administration increases the average TTR, reach higher TTR levels in the early anticoagulant phase and significantly reduce the risk of ischemic stroke events.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.